Showing 1,523 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Injectable & long-acting PrEP

Pharmaceutical corporation ViiV must provide transparency on life-saving HIV-prevention drug

Editor's pick
Médecins Sans Frontières
31 March 2023
Injectable & long-acting PrEP

Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine

Editor's pick
Medicines Patent Pool
30 March 2023
Injectable & long-acting PrEP

Cabotegravir long-acting for PrEP registrations continue in Sub-Saharan Africa

Editor's pick
ViiV press release
29 March 2023
People with limited treatment options

WEP Clinical has partnered with TaiMed Biologics to launch a Trogarzo named patient program

Editor's pick
WEP Clinical press release
24 March 2023
Access to healthcare

MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug

Editor's pick
MSF
24 March 2023
Pharmaceutical industry

Gilead Sciences, after long battle against HIV drug fraudsters, scores $175.2M in judgements

Editor's pick
FiercePharma
13 March 2023
New & experimental HIV treatments

Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

Editor's pick
Merck press release
23 February 2023
Pharmaceutical industry

Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table

Editor's pick
FiercePharma
23 February 2023
HIV treatment for children & young people

ViiV Healthcare receives EU Marketing Authorisation for Triumeq PD

Editor's pick
ViiV press release
22 February 2023
Pharmaceutical industry

Big pharma must value African lives above profits, warns head of UNAIDS

Editor's pick
The Guardian
16 February 2023
Pharmaceutical industry

Gilead Sciences Commends Convictions in Counterfeiting Scheme, Pledges Continued Commitment to Protect Patients

Editor's pick
Gilead Sciences press release
10 February 2023
Injectable & long-acting PrEP

Cabotegravir long-acting PrEP out of reach for upper middle-income nations

News
8 February 2023
Treatment for women

Not counted: clinical trials of new HIV treatments are failing women

News
3 February 2023
Pharmaceutical industry

David J. Miller and Minnesota Independent Cooperative, Inc., Convicted in Multi-Million-Dollar Prescription Drug Diversion Scheme

Editor's pick
FDA
30 January 2023
Activism & civil society

Grassroots AIDS activists fought for and won affordable HIV treatments around the world – but PEPFAR didn't change governments and pharma

Editor's pick
The Conversation
25 January 2023
Pharmaceutical industry

India’s lax oversight of pharmaceutical manufacturing imperils health around the world

Editor's pick
STAT
9 January 2023
Pharmaceutical industry

Gilead runs new 'HIV is not a crime' TV ad with André De Shields

Editor's pick
FiercePharma
5 January 2023
The search for a cure

Researchers Study CRISPR Gene Editing to Cure HIV

Editor's pick
POZ
29 December 2022
Pharmaceutical industry

CytoDyn’s former CEO indicted for securities fraud. His misleading statements hurt patients even more than investors

Editor's pick
STAT
26 December 2022
Pharmaceutical industry

Ex-Cytodyn CEO, Amarex CEO hit with multiple fraud charges

Editor's pick
FierceBiotech
26 December 2022
Injectable & long-acting HIV treatment

FDA Approves New HIV Drug for Adults with Limited Treatment Options

Editor's pick
FDA
22 December 2022
Access to healthcare

CHAI 2022 report on global access to ART

Editor's pick
i-Base
19 December 2022
Health services & systems

US: Blue Cross and Blue Shield Accused of Placing Most HIV Drugs into Highest Tiers

Editor's pick
POZ
9 December 2022
Access to healthcare

More than 100 low- and middle-income countries have now received the WHO-recommended treatment for HIV thanks to access-oriented voluntary licensing agreements

Editor's pick
Medicines Patent Pool
1 December 2022